Opus Genetics, Inc. IRD 深 沪
等待开盘 05-18 09:30:00 美东时间
4.80
-0.170
-3.42%
华盛通- 最 高4.9366
- 今 开4.89
- 成交量 91.79万股
- 最 低 4.69
- 昨 收 4.97
- 总市值 3.91亿
- 52周最高 5.81
- 市盈率 静 --
- 换手率 1.13%
- 52周最低 0.9011
- 委 比 52.54%
- 总股本 8139.55万
- 历史最高 23.08
- 量 比 0.75
- 振 幅 4.96%
- 历史最低 0.65
- 每 手 1
- 风险率 1.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Citizens Maintains Market Outperform on Opus Genetics, Lowers Price Target to $11
Citizens analyst Jonathan Wolleben maintains Opus Genetics (NASDAQ:IRD) with a Market Outperform and lowers the price target from $12 to $11.
05-13 22:21
Earnings Scheduled For May 12, 2026
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
Opus Genetics Q1 EPS $(0.75) Misses $(0.14) Estimate, Sales $2.157M Miss $2.931M Estimate
Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.14) by 435.71 percent. This is a 212.5 percent decrease over losses of $(0.24) per share from
05-12 19:07
Opus Genetics' OPGx-LCA5 Program Accepted Into FDA's Rare Disease Evidence Principles Program
Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal
05-05 04:41
美股大行评级 | 达美乐比萨惨遭10家大行下调目标价；铿腾电子、艾克尔科技、Relay 、辛普森配件制造、TFI International等获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Intellia Therapeutics"买入"评级，目标价从48美元升至58美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从7美元升至8美元
04-29 10:28
Citizens Initiates Coverage On Opus Genetics with Market Outperform Rating, Announces Price Target of $12
Citizens analyst Jonathan Wolleben initiates coverage on Opus Genetics (NASDAQ:IRD) with a Market Outperform rating and announces Price Target of $12.
04-28 21:54
美股大行评级 | 潜在涨幅172.14%！Alumis获Oppenheimer上调目标价至55美元；摩根大通首予希捷科技"超配"评级，目标价525美元
今日重点评级关注：Oppenheimer：维持Alumis"跑赢大市"评级，目标价从50美元升至55美元；美银证券：维持Rocket Pharmaceuticals"买入"评级，目标价从8美元升至9美元
03-31 16:30
Cantor Fitzgerald Initiates Coverage On Opus Genetics with Overweight Rating, Announces Price Target of $15
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Opus Genetics (NASDAQ:IRD) with a Overweight rating and announces Price Target of $15.
03-30 19:19
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
